Global clinical Xerimis operates with a US headquarters and depots in the UK and Netherlands, enabling end-to-end global clinical supply capabilities and potential for expanded international service coverage and faster regional execution.

Mid-market focus With 51-200 employees and revenue in the 50-100 million range, Xerimis serves small to mid-size pharmaceutical companies, presenting opportunities to upsell scalable supply chain services and premium support for growing clients.

End-to-end services From protocol development to labeling, shipping, distribution, and returns reconciliation, Xerimis can be positioned for comprehensive outsourcing partnerships, reducing sponsor workload and improving trial timelines.

Tech-enabled ops Adoption of cloud and identity platforms (Salesforce, Microsoft 365, Google Cloud, Azure) suggests readiness for integrated tech-enabled logistics, data visibility, and potentially a platform-driven service model for trial management.

Leadership stability Recent leadership hire for UK facility and established operations leadership indicate growth momentum and capability expansion, creating opportunities to discuss expanded capacity, new geographic deployments, and improved service levels.